Breaking News

MilliporeSigma Accelerates Scale Up of Lipids to Meet Covid Demand

One of a few companies that produces lipids in quantities needed to meet demand for mRNA therapeutics, including Pfizer-BioNTech Covid-19 vaccine.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

MilliporeSigma has launched a new, high-purity synthetic cholesterol product, nine months ahead of schedule to meet high demand for lipids, a key component of mRNA-based vaccines and therapeutics.   “Tapping into two decades’ experience of developing and manufacturing high-quality lipids, we designed a proprietary process to bring our new SAFC® synthetic cholesterol product to market nearly a year early,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma. &#8220...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters